Table 3.
Association between gene expression and antimicrobial nonsusceptibility in ESBL-producing E. coli.
| Antimicrobial agents | TEM | CTX | VEB | SHV | ||||
|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | |
| Cephalosporins | ||||||||
| Cefepime | 38 (77.6%) | 42 (82.4%) | 23 (82.1%) | 57 (79.2%) | 6 (75%) | 74 (80.4%) | 38 (86.4%) | 42 (75%) |
| Cefixime | 49 (100%) | 50 (98%) | 27 (96.4%) | 72 (100%) | 8 (100%) | 91 (98.9%) | 43 (97.7%) | 56 (100%) |
| Ceftriaxone | 29 (59.2%) | 41 (80.4%)∗ | 22 (78.6%) | 48 (66.7%) | 4 (50%) | 66 (71.7%) | 33 (75%) | 37 (66.7%) |
| Ceftazidime | 22 (44.9%) | 23 (45.1%) | 11 (39.3%) | 34 (47.2%) | 6 (75%)∗ | 39 (42.4%) | 17 (38.6%) | 28 (50%) |
| Ceftizoxime | 34 (69.4%) | 39 (76.5%) | 23 (82.1%) | 50 (69.4%) | 6 (75%) | 67 (72.8%) | 32 (12.7%) | 41 (73.2%) |
| Cefotaxime | 21 (42.9%) | 32 (62.7%)∗ | 18 (64.3%) | 35 (48.6%) | 5 (62.5%) | 48 (52.2%) | 21 (47.7%) | 32 (57.1%) |
| Carbapenems | ||||||||
| Imipenem | 14 (28.6%) | 20 (39.2%) | 11 (39.3%) | 23 (31.9%) | 3 (37.5%) | 31 (33.7%) | 15 (34.1%) | 19 (34%) |
| Meropenem | 12 (24.5%) | 21 (42.2%) | 9 (32.1%) | 24 (33.3%) | 3 (37.5%) | 30 (32.6%) | 13 (29.5%) | 20 (35.7%) |
| Aminoglycosides | ||||||||
| Amikacin | 14 (28.6%) | 28 (54.9%)∗ | 13 (46.4%) | 29 (40.3%) | 3 (37.5%) | 39 (42.4%) | 24 (54.5%)∗ | 18 (32%) |
| Gentamicin | 21 (42.9%) | 28 (54.9%) | 14 (50%) | 35 (48.6%) | 5 (62.5%) | 44 (47.8%) | 27 (61.4%)∗ | 22 (39.3%) |
| Others | ||||||||
| Ciprofloxacin | 34 (69.4%) | 42 (82.4%) | 21 (75%) | 55 (76.4%) | 5 (62.5%) | 71 (77.2%) | 39 (88.6%)∗ | 37 (66%) |
| Colistin | 39 (79.6) | 43 (84.3%) | 23 (82.1%) | 59 (81.9%) | 6 (75%) | 76 (82.6%) | 38 (86.4%) | 44 (78.6%) |
| TMP/SXT | 34 (69.4%) | 38 (74.5%) | 21 (75%) | 51 (70.8%) | 4 (50%) | 68 (73.9%) | 29 (65.9%) | 43 (76.8%) |
| Pip/TBZ | 29 (59.2%) | 29 (59.2%) | 15 (53.6%) | 43 (59.7%) | 4 (50%) | 4 (50%) | 25 (56.8% ) | 33 (59%) |
R: resistance, I: intermediate, S: sensitive, and ESBL: extended-spectrum beta-lactamase.
∗Significant differences (P < 0.05).